-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

Benzinga·01/27/2026 11:11:58
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.